Arsenic trioxide
- Generic Name
- Arsenic trioxide
- Brand Names
- Trisenox, Arsenic trioxide Accord, Arsenic trioxide Mylan, Arsenic trioxide medac
- Drug Type
- Small Molecule
- Chemical Formula
- As2O3
- CAS Number
- 1327-53-3
- Unique Ingredient Identifier
- S7V92P67HO
- Background
Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredo...
- Indication
For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression
- Associated Conditions
- Acute Promyelocytic Leukemia, Refractory Acute Promyelocytic Leukemia, Relapsed Acute Promyelocytic Leukemia
- Associated Therapies
- -
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Yang Li
- Target Recruit Count
- 50
- Registration Number
- NCT06088030
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL
- Conditions
- Interventions
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
- Target Recruit Count
- 15
- Registration Number
- NCT05497310
- Locations
- 🇲🇽
Hopsital Universitario Dr. Jose E. Gonzalez, Centro Universitario contra el Cancer, Monterrey, Nuevo Leon, Mexico
Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid
- Conditions
- Interventions
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2022-03-28
- Target Recruit Count
- 30
- Registration Number
- NCT05297123
- Locations
- 🇨🇳
First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Syros Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT04996030
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04869475
- Locations
- 🇨🇳
Department of Oncology, Ruijin Hospital, Shanghai, China
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2021-03-11
- Last Posted Date
- 2024-04-15
- Target Recruit Count
- 89
- Registration Number
- NCT04793919
- Locations
- 🇵🇹
Instituto Português de Oncologia do Porto Francisco Gentil, E. P. E., Porto, Portugal
🇮🇹AOU Policlinico Dipartimento di Pediatria, Bari, Italy
🇮🇹Ospedale Papa Giovanni XXIII - USS Oncoematologia Pediatrica, Bergamo, Italy
Arsenic Trioxide for Structural p53 Mutations
- Conditions
- Interventions
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04695223
- Locations
- 🇨🇳
Department of Medical Oncology, Shanghai Changzheng Hospital, Shanghai, China
The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- Guangzhou 8th People's Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03980665
- Locations
- 🇨🇳
Guangzhou 8th People's Hospital, Guangzhou, Guangdong, China
Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS
- Conditions
- Interventions
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 5
- Registration Number
- NCT03855371
- Locations
- 🇨🇳
Hematological department, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai, Shanghai, China
Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2022-01-04
- Target Recruit Count
- 100
- Registration Number
- NCT03751917
- Locations
- 🇮🇹
U.O.C. Oncoematologia - Istituto Oncologico Veneto Irccs, Presidio Ospedaliero S. Giacomo Apostolo, Castelfranco Veneto, Italy
🇮🇹Fondazione IRCCS Ca' Granda Osp. Maggiore Policlinico UOC Oncoematologia, Milano, Italy
🇮🇹Azienda Ospedaliera "S.Gerardo", Monza, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.